Radiopharm Theranostics Limited
$4.38
The Read: Historically, RADX stock has shown muted volatility with median moves around 3% near FDA-related catalysts, often settling within expected ranges, as clinical progress updates like Phase 2b enrollment and interim data yielded only modest price reactions without definitive late-stage or commercial breakthroughs.
Price
Overlays
Panel
RADX
Hover to view data
No Data